Inflammatory Bowel Diseases - Progress in Basic Research and Clinical ImplicationsH. Goebell, Klaus Ewe, H. Malchow |
Contents
Immunogenetics in inflammatory bowel disease | 3 |
Alterations in glycoconjugates in inflammatory bowel | 9 |
The role of sulphur metabolism and mercapto fatty acids | 17 |
Copyright | |
51 other sections not shown
Common terms and phrases
5-aminosalicylic acid acid action active acute agents antibodies antigen associated biopsies blood cause cells changes chronic Clin clinical colonic compared concentrations Crohn's disease cytokines damage decreased dose drug effect enemas evidence expression factor Figure findings fistula formation function further Gastroenterol Gastroenterology growth human immune Immunol important improvement increased indicate induced inflammation inflammatory bowel disease inhibition inhibitors interleukin-6 intestinal involved jejunum lamina propria lesions leukotriene levels LTB4 lymphocytes major mechanisms mediators metronidazole months mucosa neutrophil normal observed olsalazine oral patients patients with Crohn's patients with ulcerative placebo possible potent present production prostaglandin protein recently receptor rectal release reported response role serum severe showed shown significant significantly specific steroid stimulation substance suggest sulphasalazine surgery synthesis Table therapeutic therapy tissue topical toxic treated treatment trial ulcerative colitis